Systemic sclerosis complicating endometrial adenocarcinoma: A case report

In: Medicine · 2025 · vol. 104(20) , pp. e42553 · doi:10.1097/md.0000000000042553 · PMID:40388753 · W4410548674
article OA: gold CC0
AI-generated summary by claude@2026-06, 2026-06-13

This case report describes a 55-year-old female diagnosed with systemic sclerosis and endometrial adenocarcinoma, exploring potential shared pathophysiological mechanisms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

RATIONALE: Systemic sclerosis (SSc) is a rare systemic autoimmune disease, and it is even more uncommon to encounter it alongside a neoplasm. PATIENT CONCERNS: A 55-year-old female patient presented to our clinic with a 7-year history of cyanosis affecting multiple fingers bilaterally, accompanied by Raynaud's phenomenon, mild pain, numbness, and morning stiffness. One and a half years ago, she was diagnosed with endometrial adenocarcinoma (Federation International of Gynecology and Obstetrics stage IIIa) for frequent abdominal pain and abnormal vaginal bleeding. DIAGNOSES: Following a comprehensive physical examination and laboratory tests, she was diagnosed with SSc according to the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria. INTERVENTIONS: Although we discussed potential treatment options and prognosis with her, she ultimately declined therapy. OUTCOMES: She was lost to follow-up. LESSONS: A shared pathophysiological process may underlie the development of both SSc and malignancy, possibly driven by persistent chronic inflammation and immune dysregulation.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (8)

SciLite annotations

chemicals 3
salt paclitaxel trimethyl phosphonoacetate

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0 · commercial use OK